In case you missed it, biotech analyst Brian Skorney and industry veteran Daphne Zohar joined “The Readout Loud,” STAT’s ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday, on what proved to be an all-around poor trading session for the stock ...

GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

GSK did reiterate its financial guidance for the year, however, helped by demand for its cancer and HIV drugs: at constant exchange rates it's still expecting revenue growth of 7% to 9%, core ...